In a groundbreaking development, trials for potential treatments against the deadly Bundibugyo virus strain responsible for the ongoing Ebola outbreak in the Democratic Republic of Congo (DRC) have been initiated. This significant milestone was announced by the World Health Organization (WHO), with the first patient enrolled in the DRC on Thursday. As of June 30th, over 1,400 confirmed cases and 438 deaths have been reported in the DRC alone according to WHO data, underscoring the urgency for effective treatments. Currently, there are no approved vaccines or therapeutics available for this highly infectious disease. The current trial is jointly sponsored by the WHO, Institut National de Recherche Biomédicale in DRC, Institute of Tropical Medicine in Belgium, and the University of Oxford in the UK. Tedros Adhanom Ghebreyesus, WHO chief, emphasized the potential for these treatments to save numerous lives, stating, "While people are recovering from this disease without approved therapeutics, many more lives could be saved with safe and effective therapeutics in our toolkit." The current outbreak, which began in May and has been declared a public health emergency by WHO, has also affected Uganda and France, with 20 confirmed cases and two deaths in Uganda, and one confirmed case in France. Ebola, caused by a virus that attacks the body's immune system and organs, typically infects animals such as fruit bats but can spread among humans. Vaccines must be developed for each individual species of Ebola, with six known species, but only three are known to cause outbreaks. The trial marks a crucial step forward in the global fight against this deadly disease.